View in EDS

The MELimmune score-prognostic factors for overall survival in advanced melanoma and anti-PD-1 monotherapy-a multicentre, retrospective cohort study.

Saved in:
Bibliographic Details
Title: The MELimmune score-prognostic factors for overall survival in advanced melanoma and anti-PD-1 monotherapy-a multicentre, retrospective cohort study.
Authors: Lobo-Martins S; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Instituto Medicina Molecular João Lobo Antunes, LCosta Lab-Lisbon School of Medicine, Lisbon, Portugal., Martins-Branco D; Instituto Português de Oncologia Lisboa Francisco Gentil, Lisbon, Portugal., Semedo PM; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal., Alvim CM; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Instituto Medicina Molecular João Lobo Antunes, LCosta Lab-Lisbon School of Medicine, Lisbon, Portugal., Monteiro AM; Instituto Português de Oncologia Lisboa Francisco Gentil, Lisbon, Portugal., Vendrell I; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal., Gouveia E; Instituto Português de Oncologia Lisboa Francisco Gentil, Lisbon, Portugal., Passos MJ; Instituto Português de Oncologia Lisboa Francisco Gentil, Lisbon, Portugal., Costa L; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Instituto Medicina Molecular João Lobo Antunes, LCosta Lab-Lisbon School of Medicine, Lisbon, Portugal.; Lisbon School of Medicine, Lisbon, Portugal., Mansinho A; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Instituto Medicina Molecular João Lobo Antunes, LCosta Lab-Lisbon School of Medicine, Lisbon, Portugal., de Sousa RT; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Instituto Medicina Molecular João Lobo Antunes, LCosta Lab-Lisbon School of Medicine, Lisbon, Portugal.
Source: Immuno-oncology technology [Immunooncol Technol] 2025 Feb 03; Vol. 25, pp. 101043. Date of Electronic Publication: 2025 Feb 03 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 9918281581106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0188 (Electronic) Linking ISSN: 25900188 NLM ISO Abbreviation: Immunooncol Technol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40099013
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The MELimmune score-prognostic factors for overall survival in advanced melanoma and anti-PD-1 monotherapy-a multicentre, retrospective cohort study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lobo-Martins+S%22">Lobo-Martins S</searchLink>; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Instituto Medicina Molecular João Lobo Antunes, LCosta Lab-Lisbon School of Medicine, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Martins-Branco+D%22">Martins-Branco D</searchLink>; Instituto Português de Oncologia Lisboa Francisco Gentil, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Semedo+PM%22">Semedo PM</searchLink>; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Alvim+CM%22">Alvim CM</searchLink>; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Instituto Medicina Molecular João Lobo Antunes, LCosta Lab-Lisbon School of Medicine, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Monteiro+AM%22">Monteiro AM</searchLink>; Instituto Português de Oncologia Lisboa Francisco Gentil, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Vendrell+I%22">Vendrell I</searchLink>; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Gouveia+E%22">Gouveia E</searchLink>; Instituto Português de Oncologia Lisboa Francisco Gentil, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Passos+MJ%22">Passos MJ</searchLink>; Instituto Português de Oncologia Lisboa Francisco Gentil, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Costa+L%22">Costa L</searchLink>; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Instituto Medicina Molecular João Lobo Antunes, LCosta Lab-Lisbon School of Medicine, Lisbon, Portugal.; Lisbon School of Medicine, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22Mansinho+A%22">Mansinho A</searchLink>; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Instituto Medicina Molecular João Lobo Antunes, LCosta Lab-Lisbon School of Medicine, Lisbon, Portugal.<br /><searchLink fieldCode="AU" term="%22de+Sousa+RT%22">de Sousa RT</searchLink>; Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.; Instituto Medicina Molecular João Lobo Antunes, LCosta Lab-Lisbon School of Medicine, Lisbon, Portugal.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918281581106676%22">Immuno-oncology technology</searchLink> [Immunooncol Technol] 2025 Feb 03; Vol. 25, pp. 101043. <i>Date of Electronic Publication: </i>2025 Feb 03 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9918281581106676 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2590-0188 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225900188%22">25900188 </searchLink><i>NLM ISO Abbreviation: </i>Immunooncol Technol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40099013
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.iotech.2025.101043
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 101043
    Titles:
      – TitleFull: The MELimmune score-prognostic factors for overall survival in advanced melanoma and anti-PD-1 monotherapy-a multicentre, retrospective cohort study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lobo-Martins S
      – PersonEntity:
          Name:
            NameFull: Martins-Branco D
      – PersonEntity:
          Name:
            NameFull: Semedo PM
      – PersonEntity:
          Name:
            NameFull: Alvim CM
      – PersonEntity:
          Name:
            NameFull: Monteiro AM
      – PersonEntity:
          Name:
            NameFull: Vendrell I
      – PersonEntity:
          Name:
            NameFull: Gouveia E
      – PersonEntity:
          Name:
            NameFull: Passos MJ
      – PersonEntity:
          Name:
            NameFull: Costa L
      – PersonEntity:
          Name:
            NameFull: Mansinho A
      – PersonEntity:
          Name:
            NameFull: de Sousa RT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 02
              Text: 2025 Feb 03
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2590-0188
          Numbering:
            – Type: volume
              Value: 25
          Titles:
            – TitleFull: Immuno-oncology technology
              Type: main
ResultId 1